Patients with autoimmune diseases, such as spondyloarthritis, are at risk of developing inflammatory bowel disease. Here are considerations for its management and treatment.... [Read More]
(Reuters)—The U.S. Food and Drug Administration said on Wednesday that it had approved Pfizer Inc’s drug, Xeljanz, to treat adults with moderate-to-severe active ulcerative colitis. The effectiveness of Xeljanz (tofacitinib) in treating ulcerative colitis was shown in three controlled clinical trials, including two trials that showed the drug caused disease remission in about 17-18 percent… [Read More]
NEW YORK (Reuters Health)—Statin use is associated with a lower risk of developing inflammatory bowel disease (IBD), especially Crohn’s disease in older patients, new research suggests. “Prior studies have suggested that statins can decrease inflammation and may improve IBD in patients who already have the disease. To our knowledge, this is the first study to show… [Read More]
NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) show imbalance in their fungal intestinal microbiota, according to new findings. “The fungal microbiota is a new actor to take into account in the pathogenesis of IBD and potentially in other diseases,” Dr. Harry Sokol of Hospital Saint-Antoine in Paris, an author of the new study,… [Read More]
NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) commonly develop skin lesions related to anti-tumor necrosis factor (anti-TNF) medications, according to a retrospective study. “We were most surprised by the relatively high percentage (30%) of patients developing skin problems while being treated with anti-TNF agents,” Dr. Isabelle Cleynen from KU Leuven, Belgium, tells Reuters… [Read More]
(Reuters Health)—Doctors know smoking can increase the risk for certain common inflammatory bowel diseases (IBD), but many patients haven’t gotten the message, a new study suggests. Out of 239 patients with two common types of IBD (Crohn’s disease and ulcerative colitis) only half were aware of the smoking risks associated with these conditions. “The take-home… [Read More]
Sarcoidosis and IgG4-related disease (IgG4-RD) are both immune-mediated, often multi-organ, diseases of uncertain etiology capable of presenting with diverse clinical manifestations. Many clinical features are common to both conditions, including hypergammaglobulinemia, the ability to form inflammatory masses and involvement of the lymph nodes, lacrimal glands, salivary glands, meninges and lungs. Although imaging modalities, such as… [Read More]
Laura Coates, MBChB, MRCP, PhD, described & compared the intricacies of different outcome measures, as well as implications for clinical practice & trials, for patients with psoriatic arthritis.... [Read More]
Experts at ACR Convergence 2020 addressed how diet & the body’s microbiome affect chronic diseases.... [Read More]
NEW YORK (Reuters Health)—Patients with preexisting autoimmune disease (AIDs) are not at increased risk for immune-related adverse events from immune checkpoint inhibitor (ICI) therapy, although these adverse events may be more likely in patients with inflammatory bowel disease (IBD), new research indicates. “Therefore, we encourage physicians not to withhold ICI in most common AIDs. However,… [Read More]